Speaker Profile

Ph.D., Global Head of R&D, Viome

Biography
As Global Head of R&D for the vaccine group at GSK, Dr. Hanon oversaw more than 3,500 employees across 50 countries dedicated to delivering discovery, development and management activities for the company's vaccine efforts. Dr. Hanon was responsible for the shared science and technology platforms supporting the entire vaccine business, managing technical development, clinical immunology, and preclinical stages of vaccine developments. Today, Dr. Hanon leads Viome's therapeutics efforts, leading our science team to identify host/microbial interactions from Viome's unique database of gene expression and to turn this knowledge into vaccines and drugs to prevent and intercept chronic diseases.

Talk
Reinventing Research & Development For Better Solutions Against Chronic Disorders
Viome has developed a unique platform capable of sequencing and quantifying RNA molecules from host and its microbiome at population scale. When combined with Artificial Intelligence, this platform allows to decipher the biological mechanisms underlying specific pathologies and paves the way for the discovery of better solutions against chronic conditions.


 Session Abstract – PMWC 2022 Silicon Valley


Understanding mechanism of action and translating microbiome science into commercially viable therapeutics remains the biggest challenge in this emerging field. With that said, pharma and biotech across many different therapeutic indications and modalities are united in this global effort to bring novel microbiome-based therapies and diagnostics into the clinical domain. This session will include some of the most impactful and promising areas of the Microbiome field and panel discussions on the challenges for faster adoption.

Sessions:

Microbiome and Cancer
Jennifer Wargo, MD Anderon
Sandrine Miller-Montgomery, UCSD

The Gut/Brain Microbiome
Mary Conrad, Axial Biotherapeutics
Chris Reyes, Bloom Science
Rosa Krajmalnik-Brown, Arizona State University

The Role of the Human Gut Microbiome on Various Diseases
Colleen Cutcliffe, Pendulum Therapeutics
Tor Savidge, Baylor College of Medicine
Nikole Kimes, Siolta Therapeutics
Sarkis Mazmanian, Caltech

Pharma Drug Development
Karim Dabbagh, Second Genome
Ethan Grant, Gilead
Matthew Henn, Seres

Direct-To-Consumer Testing/Technologies
Kiran Krishnan, Microbiome Labs
Nathan Price, Onegevity
Nicole Scott, Cybele
Emmanuel Hanon, Viome

Regulatory Perspective
Scott Jackson, NIST

Synthetic Biology in Microbiome
Jeff Hasty, UCSD

AI & ML in Microbiome
Kaja Milanowska-Zabel, Ardigen